Equities
Health CareMedical Equipment and Services
  • Price (USD)357.04
  • Today's Change8.00 / 2.29%
  • Shares traded487.67k
  • 1 Year change+26.30%
  • Beta1.1010
Data delayed at least 15 minutes, as of Jul 01 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Waters Corporation offers analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. The Company's segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments. It operates directly in over 35 countries and has products available in more than 100 countries.

  • Revenue in USD (TTM)2.98bn
  • Net income in USD657.02m
  • Incorporated1991
  • Employees7.60k
  • Location
    Waters Corp34 MAPLE STMILFORD 01757-3604United StatesUSA
  • Phone+1 (508) 478-2000
  • Fax+1 (508) 872-1990
  • Websitehttps://www.waters.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
WAT:NYQ since
announced
Transaction
value
Optofluidics IncDeal completed20 May 202520 May 2025Deal completed-0.42%--
Data delayed at least 15 minutes, as of Jul 01 2025 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revvity Inc2.77bn296.04m11.40bn11.00k39.941.5115.984.122.422.3522.7063.960.21483.054.59251,806.202.304.312.494.8456.2558.5010.6915.782.9914.590.29326.520.162-0.908657.704.201.274.56
Solventum Corp8.31bn379.00m13.12bn22.00k34.864.0214.221.582.182.1847.6918.850.56834.267.74377,636.402.59--3.05--54.71--4.55--0.85231.930.7081--0.6954---64.41------
Align Technology Inc3.98bn409.56m13.72bn20.95k34.463.6524.473.455.495.4953.4151.940.64954.553.96190,061.706.6813.909.9420.5069.9271.2410.2920.951.08--0.000.003.5410.69-5.32-0.9865-5.04--
Cooper Companies Inc3.99bn414.20m14.20bn16.00k34.501.7118.253.562.062.0619.8641.540.32611.585.43249,262.503.398.723.689.7367.2065.7010.3926.351.236.800.23780.2828.417.9833.34-3.177.59--
Hologic Inc4.03bn556.70m14.52bn7.06k27.513.1417.013.612.372.3717.3120.730.46662.576.24570,083.606.4513.127.2715.2056.4460.8213.8324.752.52110.530.3540.00-0.00253.6673.14--4.30--
Illumina Inc4.34bn-965.00m15.10bn8.97k--6.41--3.48-6.10-6.1027.2314.890.53472.606.36483,500.60-11.90-10.33-14.50-12.1566.3465.65-22.25-25.301.4817.300.4566---2.934.29-5.34---9.34--
Baxter International Inc10.77bn-277.00m15.54bn38.00k--2.1922.041.44-0.5388-1.1021.0313.800.43882.645.04283,447.40-1.09-0.8441-1.37-1.0336.7338.63-2.49-2.031.403.650.5882--2.66-1.31-293.68---8.524.12
West Pharmaceutical Services Inc2.90bn467.20m15.72bn10.60k34.375.8625.645.436.376.3739.4737.370.80214.635.30273,188.7012.5615.6115.0018.7034.5438.0015.6618.842.03--0.071610.20-1.929.48-16.9715.3124.435.84
Zimmer Biomet Holdings Inc7.70bn913.40m18.05bn17.00k20.211.469.362.344.514.5138.0662.630.35290.96225.17452,852.904.192.344.752.6871.0571.1811.887.601.466.460.366537.523.85-0.7725-11.742.05-3.690.00
Waters Corp2.98bn657.02m20.77bn7.60k31.6810.5824.416.9611.0211.0250.0432.980.65562.314.45392,533.3014.4418.4118.0223.4659.2758.7122.0222.811.2813.770.4260.000.06674.22-0.68511.61-2.75--
Insulet Corp2.20bn402.20m22.11bn3.90k56.5416.6145.5010.055.565.5629.7218.910.71611.496.08563,820.5013.106.0015.507.0370.3967.0518.299.223.6349.390.56030.0022.0722.92102.76104.84-4.75--
Steris PLC5.46bn610.12m23.63bn17.79k39.003.5821.724.336.166.2055.1167.180.51484.875.32306,938.505.775.046.365.5144.0143.7511.2010.691.3912.760.23637.516.2412.4910.648.4011.528.99
Data as of Jul 01 2025. Currency figures normalised to Waters Corp's reporting currency: US Dollar USD

Institutional shareholders

46.61%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20257.00m11.77%
Fundsmith LLPas of 31 Mar 20254.83m8.13%
BlackRock Fund Advisorsas of 31 Mar 20253.85m6.49%
AllianceBernstein LPas of 31 Mar 20253.07m5.17%
SSgA Funds Management, Inc.as of 31 Mar 20252.64m4.44%
Geode Capital Management LLCas of 31 Mar 20251.51m2.54%
Massachusetts Financial Services Co.as of 31 Mar 20251.45m2.45%
Walter Scott & Partners Ltd.as of 31 Mar 20251.44m2.42%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 2025976.94k1.64%
Invesco Capital Management LLCas of 31 Mar 2025927.91k1.56%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.